17 June 2019
EMA/COMP/290416/2019
Inspections, Human Medicines Pharmacovigilance and Committees Division

Committee for Orphan Medicinal Products (COMP)

Draft agenda for the meeting on 18-20 June 2019

Chair: Violeta Stoyanova-Beninska – Vice-Chair: Armando Magrelli

18 June 2019, 09:00-19:30, room 2A

19 June 2019, 08:30-19:30, room 2A

20 June 2019, 08:30-16:00, room 2A

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the COMP meeting reports once the procedures are finalised.

Of note, this agenda is a working document primarily designed for COMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the COMP plenary session to be held 18-20 June 2019. See June 2019 COMP minutes (to be published post July 2019 COMP meeting).

1.2. Adoption of agenda

COMP agenda for 18-20 June 2019.

1.3. Adoption of the minutes

COMP minutes for 21-23 May 2019.

2. Applications for orphan medicinal product designation

2.1. For opinion

2.1.1. - EMA/OD/0000004238

Treatment of spinal cord injury

Action: For adoption, Oral explanation to be held on 18 June 2019 at 11:00

2.1.2. - EMA/OD/0000003689

Treatment of Gaucher disease

Action: For adoption, Oral explanation to be held on 18 June 2019 at 09:30

2.1.3. - EMA/OD/0000004774

Treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes

Action: For adoption, Oral explanation to be held on 18 June 2019 at 14:30

2.1.4. - EMA/OD/0000005159

Treatment of non-infectious uveitis

Action: For adoption, Oral explanation to be held on 18 June 2019 at 16:00

2.1.5. - EMA/OD/0000006865

Treatment of haematopoietic stem cell transplantation

Action: For adoption, Oral explanation to be held on 19 June 2019 at 09:30

2.1.6. - EMA/OD/0000004784

Treatment of myasthenia gravis

Action: For adoption, Oral explanation to be held on 19 June 2019 at 11:30

2.1.7. - EMA/OD/0000005124

Treatment of soft tissue sarcoma

Action: For adoption, Oral explanation to be held on 19 June 2019 at 14:00

2.2. For discussion / preparation for an opinion

2.2.1. - EMA/OD/0000002952

Treatment of amyotrophic lateral sclerosis

Action: For discussion/adoption

2.2.2. - EMA/OD/0000003546

Treatment of aneurysmal subarachnoid haemorrhage

Action: For discussion/adoption

2.2.3. - EMA/OD/0000003566

Treatment of acute myeloid leukaemia

Action: For discussion/adoption

2.2.4. - EMA/OD/0000003683

Treatment of beta-thalassaemia intermedia and major

Action: For discussion/adoption

2.2.5. - EMA/OD/0000004401

Treatment of sarcoidosis

Action: For discussion/adoption

2.2.6. - EMA/OD/0000004755

Treatment of neuroblastoma

Action: For discussion/adoption

2.2.7. - EMA/OD/0000004845

Treatment of acute myeloid leukaemia

Action: For discussion/adoption

2.2.8. - EMA/OD/0000004919

Treatment of graft loss in solid organ transplantation

Action: For discussion/adoption

2.2.9. - EMA/OD/0000005579

Treatment of cystic fibrosis

Action: For discussion/adoption

2.2.10. - EMA/OD/0000005689

Treatment of haemophilia B

Action: For discussion/adoption

2.2.11. - EMA/OD/0000005861

Treatment of myelodysplastic syndromes

Action: For discussion/adoption

2.2.12. - EMA/OD/0000005898

Treatment of Huntington’s disease

Action: For discussion/adoption

2.2.13. - EMA/OD/0000006005

Treatment of primary biliary cholangitis

Action: For discussion/adoption

2.2.14. - EMA/OD/0000006043

Treatment of neurofibromastosis type I

Action: For discussion/adoption

2.2.15. - EMA/OD/0000006091

Treatment of WHIM syndrome

Action: For discussion/adoption

2.2.16. - EMA/OD/0000006186

Treatment of myelodysplastic syndromes

Action: For discussion/adoption

2.2.17. - EMA/OD/0000006189

Treatment of subarachnoid haemorrhage

Action: For discussion/adoption

2.2.18. - EMA/OD/0000006192

Treatment of pneumonia caused by *Pseudomonas aeruginosa*

Action: For discussion/adoption

2.2.19. - EMA/OD/0000006314

Treatment of fibromyalgia

Action: For discussion/adoption

2.2.20. - EMA/OD/0000006345

Treatment of West syndrome

Action: For discussion/adoption

2.2.21. - EMA/OD/0000006379

Treatment of hepatitis D virus infection

Action: For discussion/adoption

2.2.22. - EMA/OD/0000006380

Treatment of marginal zone lymphoma

Action: For discussion/adoption

2.2.23. - EMA/OD/0000006618

Treatment in haematopoietic stem cell transplantation

Action: For discussion/adoption

2.3. Revision of the COMP opinions

None

2.4. Amendment of existing orphan designations

None

2.5. Appeal

None

2.6. Nominations

2.6.1. New applications for orphan medicinal product designation - Appointment of COMP rapporteurs

Action: For adoption

Document(s) tabled:
OMPD applications - appointment of rapporteurs at the 18-20 June 2019 COMP meeting

2.7. Evaluation on-going

Twelve applications for orphan designation will not be discussed as evaluation is ongoing.

Action: For information

Notes: See 7.8.1. Table 6. Evaluation Ongoing.

3. Requests for protocol assistance with significant benefit question

3.1. Ongoing procedures

3.1.1. -

Treatment of diffuse large B-cell lymphoma

Action: For adoption

3.1.2. - -

Treatment of beta-thalassaemia intermedia and major

Action: For adoption

3.1.3. -

Treatment of spinal muscular atrophy

Action: For adoption

3.1.4. -

Treatment of immune thrombocytopenia

Action: For adoption

3.1.5. -

Treatment of multiple myeloma

Action: For adoption

3.1.6. -

Treatment of transthyretin-mediated amyloidosis

Action: For adoption

3.1.7. -

Treatment of medullary thyroid carcinoma

Action: For adoption

3.1.8. -

Treatment of acute myeloid leukaemia

Action: For adoption

3.2. Finalised letters

3.2.1. -

Treatment of idiopathic pulmonary fibrosis

Action: For information

3.2.2. -

Treatment of tuberculosis

Action: For information

3.2.3. -

Treatment of Niemann-Pick disease, type C

Action: For information

3.3. New requests

3.3.1. -

Treatment of biliary tract cancer

Action: For information

3.3.2. -

Treatment of naevoid basal-cell carcinoma syndrome (Gorlin syndrome)

Action: For information

4. Review of orphan designation for orphan medicinal products at time of initial marketing authorisation

4.1. Orphan designated products for which CHMP opinions have been adopted

4.1.1. Cufence - trientine dihydrochloride – EMEA/H/C/004111, EMEA/OD/043/03, EU/3/03/172

Univar BV; Treatment of Wilson's disease

Action: For information

Withdrawal request received 03 June 2019.

4.2. Orphan designated products for discussion prior to adoption of CHMP opinion

4.2.1. - larotrectinib - EMEA/H/C/004919

Bayer AG;

a) Treatment of salivary gland cancer EMA/OD/213/17, EU/3/18/1995

b) Treatment of soft tissue sarcoma EMA/OD/184/15, EU/3/15/1606

c) Treatment of glioma EMA/OD/116/18, EU/3/18/2097

d) Treatment of papillary thyroid cancer EMA/OD/117/18, EU/3/18/2098

Action: For discussion/adoption

4.2.2. - polatuzumab vedotin – EMEA/H/C/004870, EMA/OD/231/17, EU/3/18/2013, EMA/OD/0000003161

Accelerated assessment

Roche Registration GmbH; Treatment of diffuse large B-cell lymphoma

Action: For discussion/adoption

4.2.3. - tagraxofusp – EMEA/H/C/005031, EMA/OD/064/15, EU/3/15/1567, EMA/OD/0000004627

Accelerated assessment

TMC Pharma (EU) Limited; Treatment of blastic plasmacytoid dendritic cell neoplasm

Action: For discussion/adoption

4.2.4. - Onasemnogene abeparvovec – EMEA/H/C/004750, EMA/OD/028/15, EU/3/15/1509, EMA/OD/0000003028

AveXis Netherlands B.V.; Treatment of spinal muscular atrophy

Action: For discussion/adoption

4.2.5. - viable T-cells - EMEA/H/C/002397, EMA/OD/008/16, EU/3/16/1678

Kiadis Pharma Netherlands B.V.; Treatment in haematopoietic stem cell transplantation

Action: For information

4.2.6. – cannabidiol - EMEA/H/C/004675

GW Pharma (International) B.V;

a) Treatment of Dravet syndrome EMA/OD/083/14, EU/3/14/1339

b) Treatment of Lennox-Gastaut syndrome EMA/OD/275/16, EU/3/17/1855

Action: For discussion/adoption

4.2.7. – enasidenib - EMEA/H/C/004324, EMA/OD/253/15 - EU/3/16/1640, EMA/OD/0000007422

Celgene Europe B.V.; Treatment of acute myeloid leukaemia

Action: For discussion/adoption

4.3. Appeal

None

4.4. On-going procedures

Action: For information

Document(s) tabled:
Review of orphan designation for OMP for MA - On-going procedures

4.5. Orphan Maintenance Reports

Action: For information

5. Review of orphan designation for authorised orphan medicinal products at time marketing authorisation extension

5.1. After adoption of CHMP opinion

None

5.2. Prior to adoption of CHMP opinion

5.2.1. Imbruvica – ibrutinib - EMEA/H/C/003791/II/0046, EMA/OD/185/13, EU/3/14/1264, EMA/OD/0000002783

Janssen-Cilag International NV; Treatment of lymphoplasmacytic lymphoma

Action: For discussion/adoption

5.3. Appeal

None

5.4. On-going procedures

Action: For information

Document(s) tabled:
Review of orphan designation for OMP for MA extension - On-going procedures

6. Application of Article 8(2) of the Orphan Regulation

None

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the COMP

7.1.1. Strategic Review & Learning meetings

Romanian presidency meeting held in Rome on 27-28 May.

Document tabled:
Report from the meeting

7.1.2. Protocol Assistance Working Group (PAWG)

Proposed meeting time on 18 June 2019 at 18:30

Document tabled:
PAWG draft agenda for 18 June 2019 meeting

7.2. Coordination with EMA Scientific Committees or CMDh-v

7.2.1. Recommendations on eligibility to PRIME – report from CHMP

Action: For information

Document(s) tabled:
PRIME eligibility requests - list of adopted outcomes May 2019

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

7.3.1. Working Party with Patients' and Consumers' Organisations (PCWP)

Action: For information

7.3.2. Working Party with Healthcare Professionals' Organisations (HCPWP)

Action: For information

7.4. Cooperation within the EU regulatory network

7.4.1. European Commission

None

7.5. Cooperation with International Regulators

7.5.1. Food and Drug Administration (FDA)

Action: For information

Notes: Monthly teleconference

7.5.2. Japanese Pharmaceuticals and Medical Devices Agency (PMDA)

Action: For information

Notes: Ad hoc basis meeting

7.5.3. The Therapeutic Goods Administration (TGA), Australia

Action: For information

Notes: Ad hoc basis meeting

7.5.4. Health Canada

Action: For information

Notes: Ad hoc basis meeting

7.6. Contacts of the COMP with external parties and interaction with the Interested Parties to the Committee

None

7.7. COMP work plan

None

7.8. Planning and reporting

7.8.1. List of all applications submitted/expected and the COMP rapporteurship distribution of valid applications submitted in 2019

Action: For information

7.8.2. Overview of orphan marketing authorisations/applications

Action: For information

8. Any other business

8.1. EMA Business Pipeline activity and Horizon scanning

Action: For information

Document tabled:
Q2/2019 Update of the Business Pipeline report for the human scientific committees

8.2. Handling of competing interests

Reminder training

Action: for discussion

Document tabled:
2019 04_Handling of competing interests_training to committees

9. Explanatory notes

The notes below give a brief explanation of the main sections and headings in the COMP agenda and should be read in conjunction with the agenda or the minutes.

Abbreviations / Acronyms

CHMP: Committee for Medicinal Product for Human Use

COMP: Committee for Orphan Medicinal Products

EC: European Commission

OD: Orphan Designation

PA: Protocol Assistance

PDCO: Paediatric Committee

PRAC: Pharmacovigilance and Risk Assessment Committee

SA: Scientific Advice

SAWP: Scientific Advice Working Party

Orphan Designation *(section 2 Applications for orphan medicinal product designation)*

The orphan designation is the appellation given to certain medicinal products under development that are intended to diagnose, prevent or treat rare conditions when they meet a pre-defined set of criteria foreseen in the legislation. Medicinal products which get the orphan status benefit from several incentives (fee reductions for regulatory procedures (including protocol assistance), national incentives for research and development, 10-year market exclusivity) aiming at stimulating the development and availability of treatments for patients suffering from rare diseases.

Orphan Designations are granted by Decisions of the European Commission based on opinions from the COMP. Orphan designated medicinal products are entered in the Community Register of Orphan Medicinal Products.

Protocol Assistance *(section 3 Requests for protocol assistance with significant benefit question)*

The protocol assistance is the help provided by the Agency to the sponsor of an orphan medicinal product, on the conduct of the various tests and trials necessary to demonstrate the quality, safety and efficacy of the medicinal product in view of the submission of an application for marketing authorisation.

Sponsor

Any legal or physical person, established in the Community, seeking to obtain or having obtained the designation of a medicinal product as an orphan medicinal product.

Maintenance of Orphan Designation *(section 4 Review of orphan designation for orphan medicinal products for marketing authorisation).*

At the time of marketing authorisation, the COMP will check if all criteria for orphan designation are still met. The designated orphan medicinal product should be removed from the Community Register of Orphan Medicinal Products if it is established that the criteria laid down in the legislation are no longer met.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/